TARRYTOWN, NY, April 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that Chief Executive Officer Howard Weisman will ring the Nasdaq… Read More..

Interim financing to bridge to advancement of ongoing buyside M&A discussions and anticipated favorable midyear performance metrics for faidr M&A strategy will accelerate Auddia's plans to scale, acquire subscribers, expand internationally, and deploy to broader platforms, including automobiles BOULDER, CO, April 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Auddia… Read More..

Lipella to collaborate in anticipation of forthcoming Investigational New Drug (IND) application LP-10 is a promising potential treatment for hemorrhagic cystitis that has received Orphan Drug Designation from the FDA Lipella has successfully completed a Phase 2a clinical trial evaluating LP-10 PITTSBURGH, April 17, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc.… Read More..